Fluconazole
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Fluconazole: From Fungal Infections to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Fluconazole is a triazole antifungal, globally established for treating systemic fungal infections such as candidiasis and cryptococcal meningitis. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis, but this direction currently has no supporting clinical trials and no supporting literature — it is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Fungal infections (systemic mycoses, e.g. candidiasis, cryptococcal meningitis) — based on the drug's established global identity; no local license record confirms this |
| Predicted New Indication | Punctate Epithelial Keratoconjunctivitis |
| TxGNN Prediction Score | 99.24% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature) |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Fluconazole is a triazole antifungal. Its mechanism of action is inhibition of fungal cytochrome P450-dependent lanosterol 14α-demethylase (CYP51), which blocks ergosterol synthesis and disrupts fungal cell membrane integrity.
Punctate epithelial keratoconjunctivitis is typically caused by viral infection (e.g. adenovirus-related epidemic keratoconjunctivitis, herpesvirus) or is idiopathic (e.g. Thygeson's superficial punctate keratitis). Only a small minority of cases overlap with fungal keratitis. Because the disease's fungal etiology is not established as a primary driver, Fluconazole's antifungal mechanism has only a low, indirect theoretical relationship to this indication rather than a direct pathophysiological match.
This assessment is further limited by data quality: the drug's formal MOA record and Taiwan/New Zealand regulatory registration are both marked as data gaps in this evidence pack, and the drug is not currently marketed in New Zealand. The similarity between the original indication and this predicted indication has not yet been formally assessed (status: pending). Overall, mechanistic plausibility is weak, and this prediction should be treated as an early-stage, unvalidated signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
Fluconazole is not currently marketed in New Zealand under this evidence pack, and no authorization records exist (total licenses: 0).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by the TxGNN model score (L5 evidence) — there are no clinical trials or published literature linking Fluconazole to punctate epithelial keratoconjunctivitis, and the mechanistic rationale is weak given the disease's predominantly viral/idiopathic etiology. Foundational drug-level data (confirmed MOA, TFDA/Medsafe warnings and contraindications, market registration) are also incomplete, which blocks even an initial safety assessment (S1).
To proceed, the following is needed:
- Official TFDA/Medsafe package insert data (warnings, contraindications) — currently a Blocking data gap
- Confirmed mechanism of action documentation from DrugBank or equivalent source
- Literature or clinical evidence establishing a fungal etiology link to punctate epithelial keratoconjunctivitis
- Drug-drug interaction (DDI) data, currently not found
- Confirmation of local market/registration status before any regulatory pathway can be scoped
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.